HK Stock Market Move | QINGSONG HEALTH (02661) rises over 14%, comprehensive health services grow strongly, Zhengyuanfang accelerates real-world scenario validation.

QINGSONG HEALTH (02661) shares moved higher today, rising 14.07% as of press time to HK$3.77, with turnover of HK$477 million. On the news front, in the first half of this year, QINGSONG HEALTH's R&D investment reached RMB53.07 million, up 50% year-on-year, as it continued to step up investment in products including the AIcare technology stack, the Dr.GPT vertical large model for healthcare, and the evidence-based medicine agent "Zhengyuanfang." Revenue from comprehensive health service packages was RMB74.55 million, up 273.5% from RMB19.96 million in the same period last year, with its revenue share rising from 3% to 20.8%; revenue from digital medical research assistance was RMB4.62 million, up 72% year-on-year. In March this year, QINGSONG HEALTH launched the evidence-based medicine agent "Zhengyuanfang," and concurrently launched "ZhengyuanfangMedClaw Collaborative," which combines Zhengyuanfang with a multi-agent collaboration framework, covering processes such as task decomposition, evidence retrieval, guideline comparison, conclusion generation and process archiving. As of June 30, 2026, Zhengyuanfang had more than 100,000 registered users and more than 80,000 certified medical professional users.